![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, April 16, 2019 5:56:56 AM
Total Monthly NORMALIZED Retail ONLY Data March-2019
Amazing Numbers – ATH Across the Board
V
TRx: 229,525 {vs 196,574; +16.76%} – Sector +12.16% -- ATH (27,543,000 vs 23,588,931)
NRx: 115,550 {vs 101,834; +13.47%} – Sector +8.90% -- ATH (13,866,000 vs 12,220,106)
Ref: 113,975 {vs 94,740; +20.30%} – Sector +15.41% -- ATH (13,677,000 vs 11,368,825)
Gen L
TRx: 267,917 {vs 246,592; +8.65%} (32,150,000 vs 29,591,019)
NRx: 125,475 {vs 119,493; +3.01%} (15,057,000 vs 14,339,116)
L
TRx: 5,838 {vs 5,531; +5.54%} (700,500 vs 663,711)
NRx: 2,375 {vs 2,184; +8.77%} (285,000 vs 262,021)
Monthly NORMALIZED Retail TRx Market Share: 45.61% vs 43.81% --- ATH
Monthly NORMALIZED Retail NRx Market Share: 47.47% vs 45.56% --- ATH
Monthly NORMALIZED Retail Refills Market Share: 43.86% vs 42.07% --- ATH
March-2019 vs. March-2018 (NORMALIZED Retail ONLY Data)
Amazing Year-On-Year Increase Across the Board, way better than non-normalized data; more than ~65% increase in TRx & more than 80% increase in NRx and we’re still in Q1 which is historically a slow Quarter
It is worth mentioning that V is driving the whole sector into positive green territory (Year-On-Year) and at the same time increasing its own Market Share
V
TRx: 229,525 {vs 139,355; +64.71%} – Sector +11.41% -- ATH (27,543,000 vs 16,722,572)
NRx: 115,550 {vs 63,834; +81.02%} – Sector +21.07% -- ATH (13,866,000 vs 7,660,139)
Ref: 113,975 {vs 75,520; +50.92%} – Sector +3.66% -- ATH (13,677,000 vs 9,062,433)
Gen L
TRx: 267,917 {vs 274,607; -2.44%} (32,150,000 vs 32,952,868)
NRx: 125,475 {vs 119,926; +4.63%} (15,057,000 vs 14,391,148)
[L
TRx: 5,838 {vs 37,786; -84.55%} (700,500 vs 4,534,315)
NRx: 2,375 {vs 17,288; -86.26%} (285,000 vs 2,074,511)
V Mar-2019 NORMALIZED Retail ONLY TRx Market Share: 45.61% vs 30.85% in Mar-2018 --- ATH
V Mar-2019 NORMALIZED Retail ONLY NRx Market Share: 47.47% vs 31.75% in Mar-2018 --- ATH
V Mar-2019 NORMALIZED Retail ONLY Ref Market Share: 43.86% vs 30.12% in Mar-2018 --- ATH
Q1-2019 vs. Q1-2018 (NORMALIZED Retail ONLY Data)
Again Amazing Year-On-Year Increase Across the Board & driving the whole sector with it
V
TRx: 623,715 {vs 394,309; +58.18%} – Sector +11.13% --- ATH (74,845,754 vs 47,317,075)
NRx: 315,574 {vs 177,155; +78.13%} – Sector +22.50% --- ATH (37,868,856 vs 21,258,611)
Ref: 308,141 {vs 217,154; +41.90%} – Sector +2.16% --- ATH (36,976,898 vs 26,058,464)
Gen L
TRx: 803,650 {vs 793,950; +1.22%} (96,438,019 vs 95,273,967)
NRx: 380,115 {vs 345,458; +10.03%} (45,613,777 vs 41,455,007)
L
TRx: 17,570 {vs 111,906; -84.30%} (2,108,380 vs 13,428,677)
NRx: 7,125 {vs 51,129; -86.06%} (855,017 vs 6,135,521)
V Q1-2019 NORMALIZED Retail TRx Market Share: 43.17% vs 30.33% in Q1-2018 -- ATH
V Q1-2019 NORMALIZED Retail NRx Market Share: 44.90% vs 30.88% in Q1-2018 --ATH
V Q1-2019 NORMALIZED Retail Ref Market Share: 41.52% vs 29.89% in Q1-2018 -- ATH
Q1-2019 vs. Q4-2018 ( NORMALIZED Retail ONLY Data)
Great Quarter Increase especially that Q1 is usually the slowest and Q4 has the best performance
V
TRx: 623,715 {vs 544,533; +14.54%} – Sector -3.72% --- ATH (74,845,754 vs 65,343,925)
NRx: 315,574 {vs 256,987; +22.80%} – Sector +2.58% --- ATH (37,868,856 vs 30,838,382)
Ref: 308,141 {vs 287,546; +7.16%} – Sector -9.02% --- ATH (36,976,898 vs 34,505,543)
Gen L
TRx: 803,650 {vs 936,135; -14.15%} (96,438,019 vs 112,336,163)
NRx: 380,115 {vs 420,099; -9.52%} (45,613,777 vs 50,411,873)
L
TRx: 17,570 {vs 20,170; -12.89%} (2,108,380 vs 2,420,452)
NRx: 7,125 {vs 8,081; -11.83%} (855,017 vs 969,726)
V Q1-2019 NORMALIZED Retail TRx Market Share: 43.17% vs 36.28% in Q4-2019 -- ATH
V Q1-2019 NORMALIZED Retail NRx Market Share: 44.90% vs 37.51% in Q4-2019 --ATH
V Q1-2019 NORMALIZED Retail Ref Market Share: 41.52% vs 35.25% in Q4-2019 -- ATH
Recent AMRN News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM